Compare PPL & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPL | WST |
|---|---|---|
| Founded | 1920 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 20.2B |
| IPO Year | N/A | N/A |
| Metric | PPL | WST |
|---|---|---|
| Price | $35.03 | $274.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $40.75 | ★ $345.75 |
| AVG Volume (30 Days) | ★ 6.5M | 691.8K |
| Earning Date | 02-12-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.11% | 0.32% |
| EPS Growth | ★ 32.44 | 0.17 |
| EPS | 1.47 | ★ 6.75 |
| Revenue | ★ $8,979,000,000.00 | $3,017,900,000.00 |
| Revenue This Year | $7.75 | $7.01 |
| Revenue Next Year | $5.47 | $6.20 |
| P/E Ratio | ★ $23.86 | $40.63 |
| Revenue Growth | ★ 8.42 | 4.92 |
| 52 Week Low | $31.22 | $187.43 |
| 52 Week High | $38.27 | $348.90 |
| Indicator | PPL | WST |
|---|---|---|
| Relative Strength Index (RSI) | 50.98 | 51.83 |
| Support Level | $34.08 | $264.92 |
| Resistance Level | $34.89 | $279.01 |
| Average True Range (ATR) | 0.44 | 6.69 |
| MACD | 0.19 | 0.60 |
| Stochastic Oscillator | 97.16 | 61.67 |
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.